Startup profile · funding coverage
KymaThera funding, valuation and investors
Precision-medicine biotech developing mutant-selective PI3Kα inhibitors for cancer and vascular malformations.
Keep track of KymaThera
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$80 million · October 6, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$80M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · San Diego, California, United States
Overview
KymaThera is a San Diego biotechnology company developing structure-guided small-molecule precision medicines. Its lead program, K-1728, is an investigational oral pan-mutant selective PI3Kα inhibitor designed to cover kinase- and helical-domain mutations while sparing wild-type PI3Kα.
Why KymaThera is interesting
K-1728 targets a clinically validated pathway where efficacy has been constrained by hyperglycemia and incomplete mutation coverage. The $80 million Series B is intended to carry the wholly owned program into Phase 1 and through initial clinical proof-of-concept.
Product & use cases
K-1728 is an oral PI3Kα inhibitor designed to inhibit disease-driving kinase- and helical-domain mutations while limiting inhibition of the wild-type protein. KymaThera plans development in HR-positive/HER2-negative breast cancer and PI3Kα-driven vascular malformations.
- HR-positive, HER2-negative PI3Kα-mutant breast cancer.
- PI3Kα-driven vascular malformations.
Key facts
- $80 million Series B announced as closed on October 6, 2026.
- More than $100 million raised since formation.
- Phase 1 patient dosing targeted for Q4 2026.
Funding history (newest first)
Series B
2026-10-06 $80 million- Alta Partners (lead)
- Venrock (participant)
- Foresite Capital (participant)
- J. Wood Capital (participant)
Investors in our directory
Funds linked from KymaThera's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A structure-based design platform and a claimed preclinical selectivity window that could broaden mutation coverage while reducing wild-type PI3Kα toxicity. Those benefits remain unproven in patients.
KymaThera enters a validated but competitive PI3Kα field. Its differentiation depends on whether pan-mutant coverage and wild-type sparing translate from preclinical models into human safety, exposure and response data.
-
Novartis / Piqray incumbent
Approved PI3Kα inhibitor validating the pathway, but limited by tolerability and mutation coverage.
-
Roche / Itovebi incumbent
Approved mutant-selective PI3Kα therapy that raises the clinical bar in breast cancer.
-
Eli Lilly / STX-478 direct
Mutant-selective PI3Kα program competing on selectivity, tolerability and breadth.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover KymaThera's financing or category context.
FAQs about KymaThera
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.